Pharmacoeconomics expediency of application of the combined preparation of Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of monopreparations

Aim. Conduct a comparative assessment of the pharmacoeconomic e‘cacy of using the combination Vezomni as compared to a combination of tamsulosin and solifenacin in the form of monopreparations in men with symptoms of the lower urinary tract against a benign prostatic hyperplasia. Methodology. The design of the study is a retrospective analysis of the literature data. Methods of pharmacoeconomic analysis – cost analysis, "budget impact" analysis, cost-effectiveness analysis, sensitivity analysis. Results. The use of Vezomni instead of a combination of monopreparations tamsulosin + solifenacin will reduce the burden on the budget of the state guarantee program by 11.68 % for 3 years. With a target population of 1,000 people, the savings will be 6.28 million rubles. The cost of treatment of symptoms of the lower urinary tract for 1 year will decrease by 2 340.76 rubles for 1 person. At the same cost, the use of a fixed combination will provide therapy with 13.23 % more patients than with monotherapy (1132: 1000 people, respectively). Сonclusion. The use of the combination drug Vezonmi is pharmacoeconomically justified and allows to lower the costs for the treatment of lower urinary tract symptoms that occur against the background of benign prostatic hyperplasia in comparison with the use of a monopreparations of tamsulosin and solifenacin.

1. Metodicheskie rekomendacii po ocenke vliyaniya na byudzhet v ramkah realizacii programmy gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi. M., FGBU "Centr ehkspertizy i kontrolya kachestva medicinskoj pomoshchi". 2016; 27. [Methodical recommendations for assessing the budget impact analysis on the framework of implementation of the program of state guarantees for free provision of medical care to citizens. M., FGBU "Center for Expertise and quality control of medical care". 2016. – P. 27] (In Russ)

2. Instrukciya po medicinskomu primeneniyu preparata Vezomni. [Instructions for the medical use of the drug Vezoni]. Available at: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=b2542744-68df-42c7-b602-c3c81a3fd5d2 & t = f073f800-af7a-4958-827c-2341a06e9aa5. (In Russ)

3. Maksimov VA. Optimizaciya rannej diagnostiki zabolevanij predstatel'noj zhelezy. Avtoreferat dissertacii na soiskanie uchenoj stepeni doktora medicinskih nauk. M.: 2009. [Maksimov VA. Optimization of early diagnosis of diseases of the prostate. The dissertation author's abstract on the scientific competition Degree of Doctor of Medical Sciences. – M.: 2009] (In Russ)

4. Rossijskie klinicheskie rekomendacii po urologii /pod red. Alyaeva Yu.G, Glybochko PV. i Pushkarya DYu. M.: 2013. [Russian clinical guidelines for urology / ed. Alyaeva YuG, Glibochko PV and Pushkary DYu. – M.: 2013] (In Russ)

5. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Aff airs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Eng. J. Med. 1996; 335: 533–539.

6. Lepor H., Williford WO, Barry MJ, et al. The impact of medical therapyon bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Сooperative Studies Benign Prostatic Hyperplasia Study Group. J. Urol. 1998;160:1358–1367.

7. State Drugs Register. Available at: https://grls.rosminzdrav.ru/ PriceLims.aspx

8. Analiz rezul'tatov monitoringa assortimenta i cen na zhiznenno neobhodimye i vazhnejshie lekarstvennye preparaty za fevral' 2018 goda. Roszdravnadzor. Moskva, 2018. [Analysis of the results of monitoring the range and prices for vital and essential medicines for February 2018. Roszdravnadzor. Moscow, 2018. Available at: http://www.roszdravnadzor.ru/drugs/monitoringzhnvlp/documents/50671. (In Russ)

9. Drake MJ, Chapple C, Sokol R, et al. NEPTUNE Study Group. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015 Feb; 67(2):262–70. DOI: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.

10. Metodicheskie rekomendacii po ocenke sravnitel'noj klinikoehkonomicheskoj ehffektivnosti i bezopasnosti lekarstvennogo sredstva. M., FGBU "Centr ehkspertizy i kongtrolya kachestva medicinskoj pomoshchi". 2016; 27S. [Methodical recommendations on the evaluation of the comparative clinical and economic effectiveness and safety of the medicinal product. M., FGBU "Center for Expertise and Control of Quality of Medical Care". 2016. – P. 27] (In Russ)

11. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol. Clin. North. Am. 1995;22:247–261.

12. Postanovlenie Pravitel'stva RF ot 28.08.2014 N 871 (red. ot 12.06.2017) "Ob utverzhdenii Pravil formirovaniya perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal'nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi". [Decree of the Government of the Russian Federation of 28.08.2014 N 871 (Edited on 12.06.2017). "On approval of the Rules for the formation of lists of medicinal products for medical use and the minimum range of medicines required for the provision of medical care"] (In Russ)